Evidence map›Paper›PMID 25613468›Full record

Trial reportBMC medical research methodology2015

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).

Naomi J Williams, Elizabeth M Hill, Siaw Yein Ng, Richard M Martin, Chris Metcalfe, Jenny L Donovan, Simon Evans, Laura J Hughes, Charlotte F Davies, Freddie C Hamdy and 3 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC medical research methodology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Naomi J WilliamsSchool of Social and Community Medicine, University of Bristol, based at Royal Hallamshire Hospital, Sheffield, S10 2JF, UK. naomi.williams@sth.nhs.uk.
Elizabeth M HillSchool of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK. liz.hill@bristol.ac.uk.
Siaw Yein NgSchool of Social and Community Medicine, University of Bristol, based at Freeman Hospital, High Heaton, Newcastle-upon-Tyne, NE7 7DN, UK. siawyein.Ng@nuth.nhs.uk.
Richard M MartinSchool of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK. richard.martin@bristol.ac.uk.
Chris MetcalfeSchool of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK. chris.metcalfe@bristol.ac.uk.
Jenny L DonovanSchool of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK. jenny.donovan@bristol.ac.uk.
Simon EvansRoyal United Hospital, Bath, BA1 3NG, UK. simonevans47@hotmail.com.
Laura J HughesDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. hughes_laura@outlook.com.
Charlotte F DaviesSchool of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK. charlotte.davies@bristol.ac.uk.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK. charlotte.davies@bristol.ac.uk.
David E NealDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. den22@cam.ac.uk.
Emma L TurnerSchool of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK. emma.turner@bristol.ac.uk.
CAP Cause of Death Committee

Funding

Cancer Research UK C11043/A4286Cancer Research UK C18281/A11326Cancer Research UK C18281/A15064Cancer Research UK C18281/A8145Department of Health HTA 96/20/99Medical Research Council MR/K006525/1Medical Research Council MR/K025643/1
6 · The paper itself

Abstract

backgroundIn cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers' ability to correctly guess the trial arm.

methodsOver 550 General Practitioner (GP) practices (>415,000 men aged 50-69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm.

results1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation.

conclusionsIt is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them.

trial registrationISRCTN92187251.

Indexed as

AgedCause of DeathCost-Benefit AnalysisEarly Detection of CancerGeneral PractitionersHumansMaleMass ScreeningMedical RecordsMiddle AgedProstate-Specific AntigenProstatic NeoplasmsReference StandardsResearch DesignUnited KingdomProstate-Specific Antigen

Identifiers

PMID25613468
PMCPMC4429825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.